## Pharmacogn. Mag.

A multifaceted peer reviewed journal in the field of Pharmacognosy and Natural Products www.phcog.com | www.phcog.net

## *In vitro* Screening and Evaluation of 37 Traditional Chinese Medicines for Their Potential to Activate Peroxisome Proliferator-activated Receptors-y

## Die Gao, Yonglan Zhang, Fengqing Yang, Yexin Lin, Qihui Zhang, Zhining Xia

Department of Pharmacy, College of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, P.R. China

Submitted: 10-08-2015

Revised: 08-09-2015

Published: 02-03-2016

### ABSTRACT

Background: Peroxisome proliferator-activated receptors (PPAR)-y is widely used as an attractive target for the treatment of type 2 diabetes mellitus. Thiazolidinediones, the agonists of PPARy, has been popularly utilized as insulin sensitizers in the therapy of type 2 diabetes whereas numerous severe side-effects may also occur concomitantly. **Objective:** The PPAR $\gamma$ activation activity of different polar extracts, including petroleum ether, ethyl acetate, n-butanol, residual of ethanol, the precipitate part of water and the supernatant of water extracts, from 37 traditional Chinese medicines were systematically evaluated. Materials and Methods: HeLa cells were transiently co-transfected with the re-constructed plasmids of GAL4-PPARy-ligand binding domain and pGL4.35. The activation of PPARy by different polarity extracts were evaluated based on the PPARy transactivation assay and rosiglitazone was used as positive control. Results: Seven medicines (root bark of Lycium barbarum, Anoectochilus sroxburghii, the rhizome of Phragmites australis, Pterocephalus hookeri, Polygonatum sibiricum, fruit of Gleditsia sinensis, and Epimedium brevicornu) were able to significantly activate PPARy. Conclusion: As seven medicines were able to activate PPARy, the anti-diabetic activity of them is likely to be mediated by this nuclear receptor.

**Key words:** Diabetes mellitus, different polarity extracts, peroxisome proliferator-activated receptor- $\gamma$ , traditional anti-diabetic medicines

#### **SUMMARY**

- Lots of the tested medicinal products had activation effects on activating  $\mathsf{PPAR}_{\gamma}$
- Ethyl acetate extracts of root bark of *L.barbarum*, rhizome of *Psaustralis* and fruit of *G.siasinensis* showed good PPARγ activation effect similar or higher than that of positive control, 0.5 µg/mL rosiglitazone
- Petroleum ether extracts of *A.roxburghii*, *P. hookeri*, *P. sibiricum*, *E.brevicornu* also can significantly activate PPARγ, the effects of them were higher than t0.5 µg/mL rosiglitazone
- Schisandra chinensis (Turcz.) Baill., the fruit Cornus officinalis Siebold and Zucc., Alisma plantago-aquatica L. and the root of Trichosanthes Kirilowii Maxim., traditional anti-diabetic mediciness in China, had no effects on the activation of PPARy.



Abbreviations used: PPARy: Peroxisome Proliferator-activated Receptors-y, TCMs: Traditional Chinese medicines, TZDs: Thiazolidinediones, LBD: Ligand binding domain, DMSO: Dimethyl sulfoxide, FBS: Fetal bovine serum, DMEM: Dulbecco's modified Eagle's

#### Correspondence:

medium.

Prof. Zhining Xia,

College of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, P.R. China. E-mail: tcm\_anal\_cqu@163.com **DOI:** 10.4103/0973-1296.177909





## **INTRODUCTION**

Diabetes mellitus is a metabolic disease characterized by insulin resistance coupled with a lackage of enough insulin to control blood glucose.<sup>[11]</sup> It is well-known that chronic hyperglycemia results in many diabetic complications such as diabetic nephropathy, obesity, and atherosclerosis.<sup>[2]</sup>

Peroxisome proliferator-activated receptors (PPARs) have been implicated to participate in many critical physiological and pathological processes, especially in the treatment of diabetes mellitus, obesity, and atherosclerosis.<sup>[3,4]</sup> They play important roles in the expression of various genes which are crucial to lipid and glucose metabolism.<sup>[5]</sup> There are three PPAR subtypes, PPAR $\alpha$ , PPAR $\beta/\delta$ , and PPAR $\gamma$ , which have respective expression patterns and regulate different biological processes based on the requirement of a specific tissue.<sup>[6]</sup> PPAR $\gamma$  is expressed in adipose cells as well as islet beta cells.<sup>[7]</sup> Activation of PPARγ can improve insulin sensitization and reduce the risk of the insulin resistance in adipose tissue, liver tissue, and *et al.*<sup>[8,9]</sup> The activation of it affects the

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

**Cite this article as:** Gao D, Zhang Y, Yang F, Lin Y, Zhang Q, Xia Z. *In vitro* screening and evaluation of 37 traditional chinese medicines for their potential to activate peroxisome proliferator-activated receptors-γ. Phcog Mag 2016;12:120-7.

glucose homeostasis and lipid metabolism as well as inflammation.<sup>[10]</sup> Increasing evidence indicated that the activation of PPAR $\gamma$  can promote the adipocyte differentiation, decrease the accumulation of glucose in adipose tissue.<sup>[11,12]</sup> Moreover, PPAR $\gamma$  plays an important role in the regulation of pancreatic functions and activation of PPAR $\gamma$  can decrease  $\beta$ -cell apoptosis.<sup>[13]</sup> It is also known that PPAR $\gamma$  affects glucose-stimulated insulin secretion.<sup>[14,15]</sup> Therefore, the screening of drugs which can activate PPAR $\gamma$  has great significance in the treatment of diabetes mellitus and related metabolic syndromes.

Thiazolidinediones (TZDs), the agonists of PPAR $\gamma$ , had been demonstrated to have a variety of clinical effects such as enhancing insulin sensitivity and improving glucose tolerance.<sup>[16,17]</sup> However, recently evidence demonstrates that TZDs had several side-effects such as cardiovascular risks, liver damage, weight gain, and peripheral edema.<sup>[18,19]</sup> On the other hand, traditional Chinese medicines (TCMs) with fewer side-effects have proven historically to be a potential source for drug discovery. Therefore, numbers of researches have been done to explore the activators of PPAR $\gamma$  from TCMs.<sup>[10,20]</sup>

In previous study, we developed a cell-based PPARs screening model. The model is a stable and effective assay tool to characterize the interactions between PPAR subtype and PPARs activating drugs. Only when a drug bound and activated GAL4-PPAR $\gamma$ -ligand binding domain (LBD) could the luciferase be expressed. The Z'-factor, which was a useful tool and a statistical characteristic of any given assay, was used to evaluate the reliability and the stability of our model. When the value of Z'-factor was between 0.5 and 1, suggesting that the model was suitable for drug screening. The value of Z'-factor of our model was 0.64.<sup>[21]</sup>

Herein, this study aimed to preliminary screen and to evaluate the activation of PPAR $\gamma$  by different polarity extracts from 37 TCMs on the basis of PPAR $\gamma$  transactivation assay, laying the basis of further identifying the effects of active extracts on PPAR $\gamma$ -mediated gene expression, and biological responses and isolating the active compounds from active extracts.

## **MATERIALS AND METHODS**

## Cells and reagents

HeLa cells were purchased from the Cell Center of the Chinese Academy of Medicinal Sciences (Shanghai, China). Fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM) were products of Gibco BRL (Gaithersburg, MD, USA). FUGene<sup>®</sup> HD Transfection Reagent and Bright-Glo<sup>™</sup> Luciferase Assay were purchased from Promega (Madison, WI, USA). Dimethyl sulfoxide (DMSO), penicillin, streptomycin, and rosiglitazone were provided from Sigma-Aldrich Chemical Co, Ltd (St. Louis, MO, USA).

#### Plasmid construction

pGL4.35 (luc2P/9XGAL4UAS/Hygro) Vector (Product No. E1370) and GAL4-GR Vector (Product No. E1581) were from Promega Corporation (Madison, WI, USA). The synthetic PPARγ-LBD gene sequences were inserted into GAL4-GR vector, and the sequencing of PPARγ-LBD genes was analyzed by restriction enzyme digestion (XhoI and XbaI) and gel electrophoresis. Then PPARγ-LBD replaced glucocorticoid receptor-LBD (GR-LBD) gene fusion in original GAL4-GR Vector and then formed the GAL4-PPARγ-LBD fusion protein. The pGL4.35 (luc2P/9XGAL4UAS/Hygro) vector containing GAL4 special response element of firefly luciferase was used as reporter gene.

## Collection of medicines material

The TCMs were obtained from the local drug stores, TCMs markets or production place [Table 1]. Further identification of the specimens was authenticated by Professor GuoyueZhong (Jiangxi University of TCM). All voucher specimens have been deposited at Chongqing Academy of Chinese Materia Medica, Chongqing, China.

## Preparation of different polarity extracts

The dried materials of 37 TCMs were ground into fine powder in a pulverizer, respectively. Reflux extraction was conducted in turn by petroleum ether, 70% ethanol, and water. Then, 70% ethanol extract was liquid-liquid extracted by ethyl acetate, while the concentrated segments of water were treated with absolute ethanol until the absolute ethanol reached to 60%. Afterward, the precipitate and the supernatant were collected, respectively. Finally, petroleum ether, ethyl acetate, the residual of ethanol, the precipitate, and the supernatant of water extracts were obtained. Each part was concentrated to dryness in a vacuum to afford samples for biological tests.

The positive drugs, petroleum ether, and ethyl acetate extracts were dissolved in DMSO. The residual of ethanol, the precipitate part of water, and the supernatant of water extracts were dissolved in water. All of them were stored at  $-20^{\circ}$ C.

## Cell culture

HeLa cells were grown in DMEM, containing 10% FBS and antibiotics (100 units/mL penicillin and 100  $\mu$ g/mL streptomycin). All cells were cultivated at 37°C in 5%CO<sub>2</sub> atmosphere.

## IN VITRO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS γ TRANSACTIVATION BIOASSAY

HeLa cells were seeded into 6 well-plates at a density of  $2 \times 10^5$  cells/well in DMEM containing 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin for 24 h. Then, 0.4 µg GAL4-PPARγ-LBD vector and 1.6 µg of pGL4.35 vector were transiently co-transfections into cells under the condition of FuGENE\* HD Transfection reagent. After an overnight culture, the cells were replaced into 96 well-plates with new culture medium. 24 h later, negative control, 0.5 µg/mL rosiglitazone, or test samples were added, respectively. After 24 h, the luciferase activity was detected with Bright-Glo<sup>TM</sup>.

#### Statistical analysis

Each of these samples was measured in triplicate at various concentrations. Each concentration was tested for sextuplicate. All data are expressed as the mean  $\pm$  standard deviation. The results were analyzed by one-way, and significant differences were determined by the origin 8.0. Statistical significance is displayed as P < 0.05.

## RESULTS

## The dose relationship between positive drug and the activation of peroxisome proliferator-activated receptors $\boldsymbol{\gamma}$

To select an appropriate concentration of positive drug, the activation of PPAR $\gamma$  by rosiglitazone was tested (concentration from 0.5 µg/mL to 4.0 µg/mL) by PPAR $\gamma$  transactivation bioassay. The fold activation of rosiglitazone in dose-dependence manner is shows in Figure 1. The maximum fold on the activation of PPAR $\gamma$  was 1 µg/mL, and the range of fold activation was from 3.8-to 5.8-folds activation compared to vehicle control (DMSO). On the other hand, there was little change of the fold activation when the concentration of rosiglitazone exceeded 0.5 µg/mL (the range of fold activation was from 3.2 to 5.1 folds activation). Hence, we chose 0.5 µg/mL rosiglitazone as a positive control in later experiments.

Table 1: The plants species tested for potential peroxisome proliferator-activated receptor gamma activation properties in the screening m	
able 1. The plants species tested for potential peroxisome proliferator-activated receptor damma activation properties in the screening m	
	mode
<b>When the plants species tested for potential perovision of promerator activation grants species in the selecting h</b>	moue

Number	Botanical name	Family	Part of plant	Voucher specimennumber	Local name
1	Alisma plantago-aquatica L.	Alismataceae	Root	GH828	Ze Xie
2	Ampelocissus artemisiifolia Planch.	Vitaceae	Leaves	GH829	Suan Lian Teng
3	Anemarrhena asphodeloides Bunge	Asparagaceae	Rhizome	GH830	Zhi Mu
4	Anoectochilus roxburghii (Wall.) Lindl.	Orchidaceae	Leaves	GH831	Jin Xian Lian
5	Astragalus membranaceus (Fisch.) Bunge	Leguminosae	Root	GH832	Huang Qi
6	Atractylodes lancea (Thunb.) DC.	Compositae	Rhizome	GH833	Cang Zhu
7	Clematis chinensis Osbeck	Ranunculaceae	Root stem	GH834	Wei Lin Xian
8	Cornus officinalis Siebold & Zucc.	Cornaceae	Fruit	GH835	Shan Zhu Yu
9	Crataegus pinnatifida Bunge	Rosaceae	Fruit	GH836	Shan Zha
10	Cuscuta chinensis Lam.	Convolvulaceae	Seed	GH837	Tu Si Zi
11	Cyelcobalanpsis glauca (Thunb. ex Murray) Oerst	Fagaceae	Leaves	GH838	Tie Zhou
12	Dendrobium moniliforme (L.) Sw.	Orchidaceae	Root	GH839	Shi Hu
13	Epimedium brevicornu Maxim.	Berberidaceae	Aerial parts	GH840	Yin Yang Huo
14	Gleditsia sinensis Lam.	Leguminosae	Fruit	GH841	Zhu Ya Zao
15	<i>Gynostemma pentaphyllum</i> (Thun b.) Makino	Cucurbitaceae	Whole plant	GH842	Jiao Gu Lan
16	-	-		GH843	Hui Dou Ba
17	Ligustrum lucidum W. T. Aiton	Oleaceae	Fruit	GH844	Nv Zhen Zi
18	L. barbarum L.	Solanaceae	Root bark	GH845	Di Gu Pi
19	L. barbarum L.	Solanaceae	Fruit	GH846	Gou Qi
20	Malus doumeri (Bois) Chev.	Rosaceae	Leaves	GH847	Lin Qin Ye
21	<i>Momordica charantia</i> L.	Cucurbitaceae	Fruit	GH848	Ku Gua
22	Moringa oleifera Lam.	Moringaceae	Leaves	GH849	La Mu Ye
23	M. alba L.	Moraceae	Leaves	GH850	Sang Ye
24	M. alba L.	Moraceae	Root bark	GH851	Sang Bai Pi
25	Ophiopogon japonicus (Thunb.) Ker Gawl.	Asparagaceae	Tuber	GH852	Mai Dong
26	Panax ginseng C. A. Mey.	Araliaceae	Tuber	GH853	Ren Sen
27	Phragmites australis (Cav.) Trin. ex Steud.	Gramineae	Rhizome	GH854	Lu Gen
28	Polygonatum odoratum (Mill.) Druce	Asparagaceae	Rhizome	GH855	Yu Zhu
29	Polygonatum sibiricum F. Delaroche	Liliaceae	Rhizome	GH856	Huang Jin
30	Pouzolzia zeylanica (L.) Benn.	Schisandraceae	Fruit	GH857	Wu Shui Ge
31	Pterocephalus hookeri (C. B. Clarke) Hoeck	Dipsacaceae	Leaves	GH858	Yi Shou Cao
32	Pueraria lobata (Willd.) Ohwi	Leguminosae	Root	GH859	Ge Gen
33	R. glutinosa (Gaertn.) DC.	Scrophulariaceae	Prepared tuber	GH860	Shu Di Huang
34	R. glutinosa (Gaertn.) DC.	Scrophulariaceae	Tube	GH861	Sheng Di Huang
35	Salvia miltiorrhiza Bunge	Labiatae	Root	GH862	Dan Shen
36	Schisandra chinensis (Turcz.) Baill.	Schisandraceae	Fruit	GH863	Wu Wei Zi
37	Trichosanthes kirilowii Maxim.	Cucurbitaceae	Root	GH864	Tian Hua Fen

L. barbarum: Lycium barbarum; M. alba: Morus alba; R. glutinosa: Rehmannia glutinosa



**Figure 1:** Fold activation of PPAR $\gamma$  by different dosages of rosiglitazone. The data are expressed as the means and standard deviations of three independent experiments with triplicate well. \**P* < 0.05 vehicle control dimethyl sulfoxide (set to 1.0)

# Effects of different polarity extracts on the activation of peroxisome proliferator-activated receptors $\gamma$

The activation of PPAR $\gamma$  resulted from 185 different kinds of prepared extracts from selected TCMs were tested for six concentrations, respectively. The results [Table 2] indicated that nine extracts resulted in stronger activation on PPAR $\gamma$  than rosiglitazone based on the comparisons of the maximum folds on the activation of PPAR $\gamma$ .

Ethyl acetate extract of root bark of *Lycium barbarum* had the strongest effect on activating PPAR $\gamma$  in all extracts. The maximum fold was 7.11-fold (50 µg/mL), which equal to 207% of positive drug [Figure 2a]. Besides, ethyl acetate extracts of rhizome of *Phragmites australis* and fruit of *Gleditsia sinensis* also could significantly activate PPAR $\gamma$ . The maximum fold on the activation of PPAR $\gamma$  by rhizome of *P. saustralis* was 5.69 fold, which was 137% of 0.5 µg/mL rosiglitazone [Figure 2b]. The maximum fold activation of the fruit of *G. sinensis* was 5.02-fold, about 105% that of positive control [Figure 2c].

Petroleum ether extracts of *Anoectochilu sroxburghii*, *Pterocephalus hookeri*, *Polygonatum sibiricum*, *Epimedium brevicornu* also can significantly activate PPAR<sub>γ</sub>. The maximum folds on the activation of PPAR<sub>γ</sub> by them were higher than that of positive drug. The maximum

Table 2: Summary of the results obtained by applying the screening model to 185 different polarity extracts from 37 traditional Chinese medicines

Number	Botanical name	Extracts <sup>a</sup>	Concentration at max	Max fold activation mean±SD	Percentage versus
			fold activation (µg/mL)	(positive drug fold activation)	positive drug
1	Root bark of <i>L. barbarum</i>	Ethyl acetate	50	7.11±0.60 (3.43)	207
2	Anoectochilus roxburghii	Petroleum ether	200	5.15±0.50 (3.22)	160
3	Rhizome of <i>P. australis</i>	Ethyl acetate	200	5.69±0.27 (4.16)	137
4	P. hookeri	Petroleum ether	400	4.06±0.49 (3.36)	121
5	P. sibiricum	Petroleum ether	100	4.67±0.57 (3.99)	117
6	P. hookeri	The residual of ethanol	400	$3.65 \pm 0.58$ (3.36)	109
7	P. hookeri	The supernatant of water	25	$3.61\pm0.62$ (3.36)	107
8	Fruit of G. sinensis	Ethyl acetate	50	$5.02\pm0.63$ (4.78)	105
9	E. brevicornu Boot hark of M. alha	Petroleum ether	200	$5.76\pm0.72$ (5.54) 3.17+0.22 (3.20)	104
10	A membranaceus	Fthyl acetate	100	$3.17\pm0.22(3.20)$ $3.31\pm0.62(3.36)$	99
12	A membranaceus	Petroleum ether	50	$3.51\pm0.02(3.50)$ $3.71\pm0.26(3.73)$	99
13	Clematis chinensis	Petroleum ether	200	4 83+0 76 (4 94)	98
14	Leaves of M. alba	Petroleum ether	12.5	4.37+0.56 (4.53)	96
15	P. lobata	Petroleum ether	400	4.31±0.37 (4.57)	94
16	P. sibiricum	Ethvl acetate	400	$3.67 \pm 0.62$ (3.99)	92
17	P. lobata	Ethyl acetate	200	4.13±0.38 (4.57)	91
18	Leaves of M. alba	The residual of ethanol	12.5	3.99±0.41 (4.53)	88
19	A. artemisiifolia	Petroleum ether	200	4.40±0.47 (5.07)	87
20	Cuscuta chinensis	Petroleum ether	200	4.29±0.73 (4.91)	87
21	E. brevicornu	Ethyl acetate	50	4.54±0.83 (5.54)	82
22	M. doumeri	Ethyl acetate	200	3.11±0.60 (3.82)	81
23	Hui Dou Ba	Petroleum ether	200	2.73±0.33 (3.48)	78
24	Pouzolzia zeylanica	Petroleum ether	400	2.88±0.36 (3.48)	78
25	A. artemisiifolia	Ethyl acetate	12.5	3.97±0.32 (5.07)	78
26	Cyelcobalanpsis glauca	The supernatant of water	200	3.26±0.36 (4.257)	77
27	G. pentaphyllum	Ethyl acetate	12.5	2.69±0.32 (3.65)	74
28	R. glutinosa	Petroleum ether	400	$2.90\pm0.71$ (4.25)	68
29	Root bark of <i>M. alba</i>	Ethyl acetate	400	$2.19\pm0.32(3.20)$	68
30 21	S. miltiorrniza	Ethyl acetate	50	$3.02\pm0.06$ (4.54)	66
31	C. prinarijuu Clamatis chinansis	Ethyl acetate	200	$3.00\pm0.53(4.00)$ $3.23\pm0.67(4.04)$	65
33	R alutinosa	Ethyl acetate	12.5	$2 23 \pm 0.07 (4.94)$	65
34	Hui Dou Ba	Ethyl acetate	50	2.25±0.05 (3.45)	65
35	$O_{iabonicas}$	Petroleum ether	100	$2.02\pm0.22$ (0.10) $2.08\pm0.68$ (3.32)	63
36	P. ginseng	Ethyl acetate	200	3.20±0.36 (5.10)	63
37	M. oleifera	Ethyl acetate	200	$2.54\pm0.43$ (4.10)	62
38	Rhizome of <i>P. australis</i>	Petroleum ether	25	2.56±0.43 (4.16)	61
39	G. pentaphyllum	Petroleum ether	50	2.23±0.25 (3.65)	61
40	M. oleifera	Petroleum ether	400	2.42±0.16 (4.10)	59
41	A. membranaceus	Ethyl acetate	6.25	2.17±0.34 (3.73)	58
42	O. japonicas	Ethyl acetate	50	1.90±0.14 (3.32)	57
43	A. lancea	Ethyl acetate	50	2.84±0.56 (5.01)	57
44	Fruit of G. sinensis	Petroleum ether	100	2.69±0.26 (4.78)	56
45	D. moniliforme	Ethyl acetate	100	2.60±0.35 (4.70)	55
46	Anemarrhena asphodeloides	Ethyl acetate	200	$2.53\pm0.59$ (4.67)	54
47	A. lancea	Petroleum ether	50	$2.71\pm0.53(5.01)$	54
48	S. miltiorrniza	The supernatant of water	25	$2.43\pm0.27$ (4.54)	54
49	NI. doumeri Polygonatum odoratum	Patroleum ether	200	$1.74\pm0.14(5.82)$ 2.31+0.46(4.60)	52
51	Folygonalum bablatum	Petroleum ether	400	$2.31\pm0.40$ (4.00) $2.02\pm0.51$ (4.03)	50
52	P ginseng	Petroleum ether	200	$2.02\pm0.31(4.03)$ $2.46\pm0.36(5.10)$	48
53	Hui Dou Ba	The residual of ethanol	400	$1.63\pm0.14(3.48)$	40
54	M. doumeri	Petroleum ether	200	$1.74\pm0.14(3.82)$	46
55	Fruit of L. barbarum	Ethyl acetate	400	$1.83\pm0.25$ (4.03)	45
56	S. miltiorrhiza	Petroleum ether	2.5	$2.02\pm0.17$ (4.54)	44
57	Cuscuta chinensis	Ethyl acetate	200	2.16±0.54 (4.91)	44
58	C. pinnatifida	Petroleum ether	100	2.03±0.17 (4.68)	43
59	Momordica charantia	Petroleum ether	100	2.30±0.46 (5.34)	43
60	E. brevicornu	The residual of ethanol	100	2.35±0.67 (5.54)	42
61	Ligustrum lucidum	Petroleum ether	200	1.69±0.22 (4.52)	37
62	Fruit of G. sinensis	The supernatant of water	100	1.72±0.28 (4.78)	36
63	D. moniliforme	Petroleum ether	50	1.67±0.33 (4.70)	35
64	D. moniliforme	The supernatant of water	200	1.60±0.31 (4.70)	34

<sup>a</sup>Only the extracts inducing transactivation of PPARγ have been included in this table. PPARγ: Peroxisome proliferator-activated receptor gamma; SD: Standard deviation; D. moniliforme: Dendrobium moniliforme; G. sinensis: Gleditsia sinensis; E. brevicornu: Epimedium brevicornu; C. pinnatifida: Crataegus pinnatifida; S. miltiorrhiza: Salvia miltiorrhiza; L. barbarum: Lycium barbarum; M. doumeri: Malus doumeri; P. ginseng: Panax ginseng; A. lancea: Atractylodes lancea; O. japonicas: Ophiopogon japonicas; A. membranaceus: Astragalus membranaceus; M. oleifera: Moringa oleifera; G. pentaphyllum: Gynostemma pentaphyllum; P. australis: Phragmites australis; R. glutinosa: Rehmannia glutinosa; M. alba: Morus alba; A. artemisiifolia: Ampelocissus artemisiifolia; P. lobata: Pueraria lobata; P. sibiricum: Polygonatum sibiricum; P. hookeri: Pterocephalus hookeri fold to activate PPAR $\gamma$  by *A. sroxburghii* was 5.15 fold, about 160% compared to 0.5 µg/mL rosiglitazone [Figure 3a]. The maximum fold to activate PPAR $\gamma$  by *P. hookeri* was 4.06 fold, 121% of positive control [Figure 3b]. The maximum folds on the activation of PPAR $\gamma$  by

*P. sibiricum* and *E. brevicornu* were 4.67 fold and 5.76 fold, which equaled to 117% and 104% of 0.5 µg/mL rosiglitazone [Figure 3c and d].

In addition, the residual of ethanol and the supernatant of water extracts of *P. hookeri* also had remarkable activation effects on PPARy [Figure 4a and b].



**Figure 2:** Fold activation of PPAR $\gamma$  by ethyl acetate extracts of Root bark of *Lycium barbarum*, (a) rhizome of *Phragmites australis*, (b) fruit of *Gleditsia sinensis*. (c) The data are expressed as the means and standard deviations of three independent experiments with triplicate well. \**P* < 0.05 versus vehicle control dimethyl sulfoxide, \*\**P* < 0.01 versus vehicle control dimethyl sulfoxide (set to 1.0), \**P* < 0.05 versus 0.5 µg/mL rosiglitazone, \*\**P* < 0.01 versus 0.5 µg/mL rosiglitazone



**Figure 3:** Fold activation of peroxisome proliferator-activated receptors- $\gamma$  by n-hexane extracts of *Anoectochilu sroxburghii*, (a) *Pterocephalus hookeri*, (b) *Polygonatum sibiricum*, (c) *Epimedium brevicornu* (d). The data are expressed as the means and standard deviations of three independent experiments with triplicate well. \**P* < 0.05 versus vehicle control dimethyl sulfoxide, \*\**P* < 0.01 versus vehicle control dimethyl sulfoxide (set to 1.0), \**P* < 0.05 versus 0.5 µg/mL rosiglitazone, \*\**P* < 0.01 versus 0.5 µg/mL rosiglitazone





The maximum folds on the activation of PPAR $\gamma$  by them were similar to positive drug. The maximum folds to activate PPAR $\gamma$  by the residual of ethanol and the supernatant of water extracts were 3.65 fold and 3.61 fold, which were 107% and 104% that of positive control, respectively.

However, traditionally anti-diabetic medicine including *Schisandra chinensis*, the fruit of *Calendula officinalis*, *Alisma plantago-aquatica* and the root of *Trichosanthes kirilowii*, had no effects on the activation of PPARγ.

## DISCUSSION

Nuclear receptors are large family of receptors which allow an access to the control of gene regulation. The family contains steroid receptors, metabolic receptors, retinoid receptors, Vitamin D receptor and *et al.*<sup>[22,23]</sup> They play important roles in normal development, reproduction, and metabolism.<sup>[24-26]</sup> Most nuclear receptors, share a similar basic structure that contains two important domains named LBD and DNA-binding domain. The two domains are crucial for the regulation of the transcription of nuclear receptors. Especially, the LBD fulfills the functions of ligand binding, dimerization, and recruitment of co-regulators.<sup>[27-29]</sup> Ligand binding and activation of nuclear receptor induces a conformational change of it and participates in the regulation of transcription via many approaches such as activation of phosphorylation of the receptor, replacement of corepressors by coactivators and *et al.*<sup>[30,31]</sup>

Considering that nuclear receptor family binds to a wide range of lipophilic ligands derived from daily life, targeting nuclear receptors have been a major source for the development of new drugs.<sup>[32]</sup> It is noteworthy that researchers have found some active compounds from traditional medicines which are the ligands for some of these nuclear receptors.<sup>[23,33]</sup> For example, honoliol, a compound isolated from magnolia bark, is a partial PPARγ agonist which binds directly to PPARγ LBD.<sup>[20]</sup> On accounting that honokiol can prevent hyperglycemia and weight gain in mice, it becomes a clinically interesting compound which has opportunity to replace TZDs.

In the past few decades, the prevalence of diabetes mellitus has increased, especially type 2 diabetes. Type 2 diabetes mellitus are closely related to unhealthy diet, sedentary lifestyle, as well as the rise of obesity in the population, which in turn impel the search for new preventive and treatment strategies.<sup>[34,35]</sup> In recent years, metabolic receptors from nuclear receptor family get more and more attention due to their regulation of metabolic homeostasis.<sup>[36,37]</sup> It is noteworthy that PPAR $\gamma$ , which belongs to PPAR family, is widely used as an important target for the treatment of diabetes mellitus. Ligand binding of PPAR $\gamma$  can induce the expression of a lot of genes which in turns changes the lipids and glucose metabolism.<sup>[36,39]</sup>

However, common agonists of PPARγ such as TZDs, have many serious side-effects such as cardiovascular risks, liver damage, weight gain, and peripheral edema.<sup>[40]</sup> Hence, significant research efforts have recently been undertaken to explore the potential drugs of activating PPARγ with less adverse effects.<sup>[40-43]</sup> TCMs seem to be an ideal replacement of TZDs for the treatment of hyperglycemia, insulin resistance, and the diabetic complications with less adverse effects.<sup>[44-46]</sup>

Based on the cell-based PPARs screening model.<sup>[47]</sup> In this study, thirty-seven traditionally used anti-diabetic TCMs were selected and to evaluate their activation activities of PPARy. The activations of PPARy-LBD by different polarity extracts from 37 TCMs were evaluated. The results indicated that the ethyl acetate extracts of root bark of L. barbarum, rhizome of P. saustralis and fruit of G. sinensis could significantly activate PPARy. The activities of them were higher than that of 0.5 µg/mL rosiglitazone. Besides, petroleum ether extracts of A. sroxburghii, P. hookeri, P. sibiricum, E. brevicornu also can significantly activate PPARy. The activities of them were also higher than that of 0.5 µg/mL rosiglitazone. Furthermore, the residual of ethanol and the supernatant of water extracts of P. hookeri had remarkable activation effects on PPARy. Thus, three extracts (petroleum ether, the residual of ethanol and the supernatant of water) of P. hookeri were found to have a significant effect on the activation of PPARy compared to 0.5 µg/mL rosiglitazone. On the other hand, previous studies showed that P. hookeri had good anti-inflammatory effects, and it was used to treat inflammation and analgesic in Tibet of China.<sup>[48]</sup> Other evidence also demonstrated that the ligands of PPARy can treat inflammation in the development of diabetes mellitus.[49,50] Therefore, it is speculated that the significant activation of PPARy by P. hookeri might be related to its remarkable anti-inflammatory activity.

On the contrary, we found that all extracts of *S. chinensis*, *C. officinalis*, *A. plantago-aquatica*, and the root of *T. kirilowii* could not activate PPARY. Previous studies showed that extracts of *S. chinensis* were effective when used as aldosereductase inhibitors for the treatment of diabetes mellitus.<sup>[51]</sup> The petroleum ether extract of it had PTP1B and alpha-glucosidase inhibitory activities. Moreover, schisandrols A and B, schisandrins A and B from *S. chinensis* were the ligands of pregnane X receptor, a xenobiotic receptor from nuclear receptor family.<sup>[23]</sup> Thus, it was speculated that the anti-diabetic effect of *S. chinensis* was through activating multiple targets except for PPARY. Similar to *S. chinensis*, the anti-diabetic effects of *C. officinalis*, *A. plantago-aquatica* and the root of *T. kirilowii* were not through activating PPARY.

*Momordicac harantia* also named "bitter gourd" had been found to be able to activate PPAR $\alpha$  and PPAR $\gamma$  *in vitro*.<sup>[52]</sup> In our study, we also found

it can activate PPARY. Furthermore, extracts of *Panax ginseng*, *Salvia miltiorrhiza*, and *Gynostemma pentaphyllum* also can activate PPARY.<sup>[23,53]</sup> The results were consistent with the previous study. However, among these chosen TCMs, only a few of them had been studied with regard to the PPARY activation through a PPARY transactivation assay *in vitro*. Our study firstly evaluated the PPARY activation by different polarity extracts from 37 TCMs with a PPARY transactivation assay, providing the basis of clarifying the specific mechanism, looking for other targets of activating extracts and screening the active compounds. Further studies will be focused on studying the specific mechanisms of active extracts on activating PPARY and screening of the active compounds through bio-guided separation.

## CONCLUSION

In summary, we have established that petroleum ether extracts of *A. sroxburghii*, *P. hookeri*, *P. sibiricum*, *E. brevicornu*, ethyl acetate extracts of root bark of *L. barbarum*, rhizome of *P. saustralis* and fruit of *G. sinensis* can significantly activate PPAR $\gamma$  as shown by specific activation of a PPAR $\gamma$ -LBD luciferase receptor assay. Hence, the anti-diabetic activity of them could in part be mediated by this nuclear receptor. Additional research will be necessary to further identify the effects of active extracts such as ethyl acetate extract of root bark of *L. barbarum* on PPAR $\gamma$ -mediated gene expression and biological responses. Moreover, further studies also will be done to identify the active compounds of PPAR $\gamma$ -LBD.

## Financial support and sponsorship

Financial Support of this paper is provided by The National Natural Science Foundation of China (Grant No. 21175159, No. 21275169 and No. 81202886) and The International Cooperation Project of Ministry of Science and Technology of China (Grant No. 2010DFA32680).

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Janani C, Ranjitha Kumari BD. PPAR gamma gene A review. Diabetes Metab Syndr Clin Res Rev 2014;438:1-5.
- Zephy D, Ahmad J. Type 2 diabetes mellitus: Role of melatonin and oxidative stress. Diabetes Metab Syndr 2015;9:127-31.
- Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012;23:351-63.
- Wang Yx. PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell Res 2010;20:124-37.
- Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR-agonist in treatment of diabetes: Cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem 2012;10:124-34.
- Montagner A, Rando G, Degueurce G, Leuenberger N, Michalik L, Wahli W. New insights into the role of PPARs. Prostaglandins Leukot Essent Fatty Acids 2011;85:235-43.
- Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, *et al.* Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in normal human pancreatic islet cells. Diabetologia 2000;43:1165-9.
- Amin RH, Mathews ST, Camp HS, Ding L, Leff T. Selective activation of PPARγ in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am J Physiol Endocrinol Metab 2010;298:E28-37.
- Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications – A review. Nut J 2014;13:17.
- Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, *et al.* Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): A review. Biochem Pharmacol 2014;92:73-89.
- Morales-Garcia JA, Luna-Medina R, Alfaro-Cervello C, Cortes-Canteli M, Santos A, Garcia-Verdugo JM, *et al.* Peroxisome proliferator-activated receptor ? ligands regulate neural stem cell proliferation and differentiation *in vitro* and *in vivo*. Glia 2011;59:293-307.

- 12. Grimaldi PA. The roles of PPARs in adipocyte differentiation. Prog Lipid Res 2001;40:269-81.
- Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3 '-kinase-dependent pathway. J Clin Endocrinol Metab 2005;90:6678-86.
- Kim HS, Hwang YC, Koo SH, Park KS, Lee MS, Kim KW, et al. PPAR-gamma activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic ß-cells. PLoS One 2013;8:e50128.
- Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000;49:1517-24.
- Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5.
- Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, *et al.* Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 2002;24:378-96.
- Shah P, Mudaliar S. Pioglitazone: Side effect and safety profile. Expert Opin Drug Saf 2010;9:347-54.
- Dunn FL, Higgins LS, Fredrickson J, DePaoli AM; INT- study group. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complications 2011;25:151-8.
- Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, et al. Honokiol: A non-adipogenic PPAR gamma agonist from nature. Biochim Biophys Acta 2013;1830:4813-9.
- Xia ZN, Lin YX, Guo LX, Yang FQ, Xu P, Zhang YL, *et al.* Development of a cell-based high-throughput peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of the extracts from rhizoma *Coptis.* J Asian Nat Prod Res 2013;15:225-34.
- Cookman CJ, Belcher SM. Classical nuclear hormone receptor activity as a mediator of complex concentration response relationships for endocrine active compounds. Curr Opin Pharmacol 2014;19:112-9.
- Li L, Bonneton F, Chen XY, Laudet V. Botanical compounds and their regulation of nuclear receptor action: The case of traditional Chinese medicine. Mol Cell Endocrinol 2015;401:221-37.
- Gonzalez-Sanchez E, Firrincieli D, Housset C, Chignard N. Nuclear receptors in acute and chronic cholestasis. Dig Dis 2015;33:357-66.
- Moschetta A. Nuclear receptors and cholesterol metabolism in the intestine. Atheroscler Suppl 2015;17:9-11.
- Polvani S, Tarocchi M, Tempesti S, Galli A. Nuclear receptors and pathogenesis of pancreatic cancer. World J Gastroenterol 2014;20:12062-81.
- Vincent ZA, Aurelien GA, Michielin O. Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta Mol Cell Biol Lipids 2007;1771:915-25.
- Kojetin DJ, Burris TP. Small molecule modulation of nuclear receptor conformational dynamics: Implications for function and drug discovery. Mol Pharmacol 2013;83:1-8.
- Rochel N, Moras D. Ligand binding domain of Vitamin D receptors. Curr Top Med Chem 2006;6:1229-41.
- Weatherman RV, Fletterick RJ, Scanlan TS. Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 1999;68:559-81.
- Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45:120-59.
- Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-64.
- Guo D, Wang J, Wang X, Luo H, Zhang H, Cao D, *et al.* Double directional adjusting estrogenic effect of naringin from Rhizoma drynariae (Gusuibu). J Ethnopharmacol 2011;138:451-7.
- Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: Epidemiology and treatment. Curr Diab Rep 2014;14:508.
- Van Buren DJ, Tibbs TL. Lifestyle interventions to reduce diabetes and cardiovascular disease risk among children. Curr Diab Rep 2014;14:557.
- Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001;294:1866-70.

- Senese R, Lasala P, Lseanza C, de Lange P. New avenues for regulation of lipid metabolism by thyroid hormones and analogs. Front Physiol 2014;5:475.
- Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPAR gamma) and its ligands: A review. Domest Anim Endocrinol 2002;22:1-23.
- Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog Horm Res 2001;56:239-63.
- 40. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf 2012;11:565-79.
- Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81.
- Sood V, Colleran K, Burge MR. Thiazolidinediones: A comparative review of approved uses. Diabetes Technol Ther 2000;2:429-40.
- Higgins LS, DePaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulation as a strategy for safer therapeutic PPAR gamma activation. Am J Clin Nutr 2010;91:267S-72S.
- 44. Gupta RK, Kesari AN, Murthy PS, Chandra R, Tandon V, Watal G. Hypoglycemic and antidiabetic effect of ethanolic extract of leaves of *Annona squamosa* L. in experimental animals. J Ethnopharmacol 2005;99:75-81.
- Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP. Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 2007;40:163-73.
- 46. Malviya N, Jain S, Malviya S. Antidiabetic potential of medicinal plants. Acta Pol Pharm

2010;67:113-8.

- 47. Xia ZN, Lin YX, Guo LX, Yang FQ, Xu P, Zhang YL, *et al.* Development of a cell-based high-throughput peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of the extracts from rhizoma *Coptis.* J Asian Nat Prod Res 2013;15:225-34.
- Zhang L, Hu JJ, Lin JW, Fang WS, Du GH. Anti-inflammatory and analgesic effects of ethanol and aqueous extracts of *Pterocephalus hookeri* (C.B. Clarke) Höeck. J Ethnopharmacol 2009;123:510-4.
- Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
- Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011;1812:1007-22.
- Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004;92:1-21.
- 52. Chao CY, Huang CJ. Bitter gourd (*Momordica charantia*) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 2003;10 (6 Pt 2):782-91.
- Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, et al. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 2009;150:104-13.



Zhining Xia

#### **ABOUT AUTHOR**

**Zhining Xia**, obtained his Ph. D, degree in University of Copenhagen. He is professor in the College of Chemistry and Chemical Engineering Chongqing University. Chongqing, China. His work mainly in: Medicinal plants, capillary electrophoresis, pharmaceutical analysis of Chinese medicines and nano-drug.